Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome ...Middle East

PR Newswire - News
Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome
PARAMUS, N.J., Aug. 2, 2021 /PRNewswire/ -- Epygenix Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy announced today that the European Medicines Agency (EMA) granted Orphan Medicinal Product Designation to EPX-200 for the...

Read More Details
Finally We wish PressBee provided you with enough information of ( Epygenix Therapeutics Receives Orphan Medicinal Product Designation in Europe With EPX-200 for the Treatment of Patients With Dravet Syndrome )

Also on site :